These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 17079188)

  • 1. Advances and perspectives in Leishmania cell based drug-screening procedures.
    Sereno D; Cordeiro da Silva A; Mathieu-Daude F; Ouaissi A
    Parasitol Int; 2007 Mar; 56(1):3-7. PubMed ID: 17079188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transgenic Leishmania donovani clinical isolates expressing green fluorescent protein constitutively for rapid and reliable ex vivo drug screening.
    Singh N; Gupta R; Jaiswal AK; Sundar S; Dube A
    J Antimicrob Chemother; 2009 Aug; 64(2):370-4. PubMed ID: 19525291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of the green fluorescent protein reporter system in Leishmania spp. for the in vitro and in vivo screening of antileishmanial drugs.
    Pulido SA; Muñoz DL; Restrepo AM; Mesa CV; Alzate JF; Vélez ID; Robledo SM
    Acta Trop; 2012 Apr; 122(1):36-45. PubMed ID: 22155571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colorimetric assay for screening compounds against Leishmania amastigotes grown in macrophages.
    Buckner FS; Wilson AJ
    Am J Trop Med Hyg; 2005 May; 72(5):600-5. PubMed ID: 15891135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro assays for evaluation of drug activity against Leishmania spp.
    Fumarola L; Spinelli R; Brandonisio O
    Res Microbiol; 2004 May; 155(4):224-30. PubMed ID: 15142618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A fluorometric method for evaluation of pharmacological activity against intracellular Leishmania amastigotes.
    Bilbao-Ramos P; Sifontes-Rodríguez S; Dea-Ayuela MA; Bolás-Fernández F
    J Microbiol Methods; 2012 Apr; 89(1):8-11. PubMed ID: 22310031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reporter genes facilitating discovery of drugs targeting protozoan parasites.
    Dube A; Gupta R; Singh N
    Trends Parasitol; 2009 Sep; 25(9):432-9. PubMed ID: 19720564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leishmania tarentolae: utility as an in vitro model for screening of antileishmanial agents.
    Taylor VM; Muñoz DL; Cedeño DL; Vélez ID; Jones MA; Robledo SM
    Exp Parasitol; 2010 Dec; 126(4):471-5. PubMed ID: 20685203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short report: fluorescent Leishmania: application to anti-leishmanial drug testing.
    Singh N; Dube A
    Am J Trop Med Hyg; 2004 Oct; 71(4):400-2. PubMed ID: 15516633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leishmania spp.: proficiency of drug-resistant parasites.
    Natera S; Machuca C; Padrón-Nieves M; Romero A; Díaz E; Ponte-Sucre A
    Int J Antimicrob Agents; 2007 Jun; 29(6):637-42. PubMed ID: 17353113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visceral leishmaniasis: experimental models for drug discovery.
    Gupta S;
    Indian J Med Res; 2011 Jan; 133(1):27-39. PubMed ID: 21321417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antileishmanial activity of Eugenol-rich essential oil from Ocimum gratissimum.
    Ueda-Nakamura T; Mendonça-Filho RR; Morgado-Díaz JA; Korehisa Maza P; Prado Dias Filho B; Aparício Garcia Cortez D; Alviano DS; Rosa Mdo S; Lopes AH; Alviano CS; Nakamura CV
    Parasitol Int; 2006 Jun; 55(2):99-105. PubMed ID: 16343984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of four Leishmania species constitutively expressing GFP protein. A model for drug discovery and disease pathogenesis studies.
    Patel AP; Deacon A; Getti G
    Parasitology; 2014 Apr; 141(4):501-10. PubMed ID: 24252638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA transformation of Leishmania infantum axenic amastigotes and their use in drug screening.
    Sereno D; Roy G; Lemesre JL; Papadopoulou B; Ouellette M
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1168-73. PubMed ID: 11257031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A microplate assay for Leishmania amazonensis promastigotes expressing multimeric green fluorescent protein.
    Chan MM; Bulinski JC; Chang KP; Fong D
    Parasitol Res; 2003 Mar; 89(4):266-71. PubMed ID: 12632163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo monitoring of intracellular ATP levels in Leishmania donovani promastigotes as a rapid method to screen drugs targeting bioenergetic metabolism.
    Luque-Ortega JR; Rivero-Lezcano OM; Croft SL; Rivas L
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1121-5. PubMed ID: 11257025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leishmania donovani: an in vitro study of antimony-resistant amphotericin B-sensitive isolates.
    Sharief AH; Gasim Khalil EA; Theander TG; Kharazmi A; Omer SA; Ibrahim ME
    Exp Parasitol; 2006 Dec; 114(4):247-52. PubMed ID: 16716301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracellular parasite kill: flow cytometry and NO detection for rapid discrimination between anti-leishmanial activity and macrophage activation.
    Kram D; Thäle C; Kolodziej H; Kiderlen AF
    J Immunol Methods; 2008 Apr; 333(1-2):79-88. PubMed ID: 18313691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation of antileishmanial sterol from the fruits of Cassia fistula using bioguided fractionation.
    Sartorelli P; Andrade SP; Melhem MS; Prado FO; Tempone AG
    Phytother Res; 2007 Jul; 21(7):644-7. PubMed ID: 17397117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid fluorescent assay for screening drugs on Leishmania amastigotes.
    Shimony O; Jaffe CL
    J Microbiol Methods; 2008 Oct; 75(2):196-200. PubMed ID: 18573286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.